Business Description
Checkpoint Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1628282063
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -2.43 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -114.87 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -70.3 | |||||
3-Year EBITDA Growth Rate | 12.5 | |||||
3-Year EPS without NRI Growth Rate | 8.1 | |||||
3-Year FCF Growth Rate | 5 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 5.89 | |||||
9-Day RSI | 14.47 | |||||
14-Day RSI | 22.85 | |||||
6-1 Month Momentum % | -4 | |||||
12-1 Month Momentum % | -30.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.29 | |||||
Quick Ratio | 0.29 | |||||
Cash Ratio | 0.27 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -58.7 | |||||
Shareholder Yield % | -65.88 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -50629.13 | |||||
Net Margin % | -50336.89 | |||||
FCF Margin % | -45614.43 | |||||
ROA % | -738.14 | |||||
ROIC % | -982.59 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 204.29 | |||||
EV-to-EBIT | -0.88 | |||||
EV-to-Forward-EBIT | -1.03 | |||||
EV-to-EBITDA | -0.88 | |||||
EV-to-Forward-EBITDA | -1.03 | |||||
EV-to-Revenue | 447.6 | |||||
EV-to-Forward-Revenue | 461.03 | |||||
EV-to-FCF | -0.97 | |||||
Earnings Yield (Greenblatt) % | -113.64 | |||||
FCF Yield % | -93.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Checkpoint Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.097 | ||
EPS (TTM) (€) | -3.081 | ||
Beta | 1.29 | ||
Volatility % | 70.04 | ||
14-Day RSI | 22.85 | ||
14-Day ATR (€) | 0.045664 | ||
20-Day SMA (€) | 1.5695 | ||
12-1 Month Momentum % | -30.92 | ||
52-Week Range (€) | 1.299 - 3.128 | ||
Shares Outstanding (Mil) | 35.69 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Checkpoint Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Checkpoint Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Checkpoint Therapeutics Inc Frequently Asked Questions
What is Checkpoint Therapeutics Inc(STU:CZTA)'s stock price today?
When is next earnings date of Checkpoint Therapeutics Inc(STU:CZTA)?
Does Checkpoint Therapeutics Inc(STU:CZTA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |